Omega-3
vetzuren voorkomen en bestrijden leverkanker.*
Uit
twee laboratoriumstudies blijkt dat de omega-3 vetzuren EPA en DHA, volop
aanwezig in vette vis en visolie, effectief zijn in het voorkomen en
bestrijden van leverkanker. Uit eerder studies was al gebleken dat omega-3
vetzuren bepaalde kankersoorten kunnen bestrijden. In deze studies wilden
men weten of dit ook het geval is bij leverkanker en waarom. In
tegenstelling tot het omega-6 vetzuur AA dat geen enkel effect bleek te
hebben hadden de omega-3 vetzuren DHA en EPA een duidelijk effect op de
leverkankercellen. Ten eerste werd de kankercelgroei geremd en de
enzymwerking (PARP) in de celkern bevorderd waardoor kankerceldood en DNA
herstel bevorderd wordt. Verder wordt door de omega-3 vetzuren de
hoeveelheid van het eiwit beta-catenine in kankercellen duidelijk
gereduceerd. Veel beta-catenine in cellen is gerelateerd met het ontstaan
van verschillende kankersoorten.
Omega-3
Fatty Acids Inhibit Growth Of Liver Cancer Cells
Two
new studies by a University of Pittsburgh research team suggest that omega-3
fatty acids--substances that are found in high concentrations in fish oils
and certain seeds and nuts--significantly inhibit the growth of liver cancer
cells. The studies, presented today at the annual meeting of the American
Association for Cancer Research (AACR), at the Washington Convention Center
in Washington, D.C., suggest that omega-3 fatty acids may be an effective
therapy for both the treatment and prevention of human liver cancers.
The first study, Abstract number 2679, looked at the effect and mechanism of
omega-3 and omega-6 polyunsaturated fatty acids in human hepatocellular
carcinoma cells. Hepatocellular carcinoma accounts for 80 to 90 percent of
all liver cancers and is usually fatal within three to six months of
diagnosis.
"It has been known for some time that omega-3 fatty acids can inhibit
certain cancer cells. So, we were interested in determining whether these
substances could inhibit liver cancer cells. If so, we also wanted to know
by what mechanism this inhibition occurs," said Tong Wu, M.D., Ph.D., a
member of the division of transplantation pathology, University of
Pittsburgh School of Medicine, in whose laboratory the research was
conducted.
The investigators treated the hepatocellular carcinoma cells with either the
omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
or the omega-6 fatty acid arachidonic acid (AA), for 12 to 48 hours. DHA and
EPA treatment resulted in a dose-dependent inhibition of cell growth,
whereas AA treatment exhibited no significant effect.
According to the investigators, the effect of omega-3 fatty acids on cancer
cells likely is due to the induction of apoptosis, or programmed cell death.
Indeed, the investigators found that DHA treatment induced the splitting up,
or cleavage, of an enzyme in the cell nucleus known as poly (ADP-Ribose)
polymerase, or PARP, which is involved in repairing DNA damage, mediating
apoptosis and regulating immune response. The cleavage of this enzyme is
considered a tell-tale indicator of apoptosis. Furthermore, DHA and EPA
treatment indirectly decreased the levels of another protein known as
beta-catenin, an overabundance of which has been linked to the development
of various tumors.
"Beta-catenin is known to promote cell growth and also is implicated in
tumor cell promotion. Therefore, our finding that omega-3 fatty acids can
decrease levels of beta-catenin is further evidence that these compounds
have the ability to interact on several points of pathways involved in tumor
progression," explained Dr. Wu.
In the second study, Abstract number 2680, the investigators treated
cholangiocarcinoma tumor cells with omega-3 and omega-6 fatty acids for 12
to 48 hours. Cholangiocarcinoma is a particularly aggressive form of liver
cancer that arises in the ducts that carry bile from the liver and has an
extremely high mortality rate. Again, the omega-3 fatty acids DHA and EPA
treatments resulted in a dose-dependent inhibition of cancer cell growth,
while the omega-6 fatty acid AA treatment had no significant effect.
Likewise, DHA treatment induced a cleavage form of PARP in
cholangiocarcinoma cells, and DHA and EPA treatment significantly decreased
the level of beta-catenin protein in the cells.
According to Dr. Wu, these findings suggest that omega-3 fatty acids not
only may be an effective therapy for the treatment of human liver cancers
but may also be a means of protecting the liver from steatohepatitis, a
chronic liver disease characterized by the buildup of fat in the liver and
believed to be a precursor of hepatocellular carcinoma. The next step in the
process, he said, is to test the effects of omega-3 fatty acids in mice
harboring human liver tumors.
###
This work was supported by grants from the National Cancer Institute. Kyu
Lim, Ph.D., in Dr. Wu's laboratory performed the major experiments. Other
investigators involved in these studies include Chang Han, Ph.D., and Lihong
Xu, Ph.D., all from the University of Pittsburgh.
Contact: Jim Swyers
SwyersJP@upmc.edu
(april
2006)
Printen